ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients With Graft Vs. Host Disease (COMPLETED)

This study has been completed.

Sponsored by: Schering-Plough
Information provided by: Schering-Plough
ClinicalTrials.gov Identifier: NCT00034645
  Purpose

This trial is in high risk patients to determine the safety, tolerance and efficacy of posaconazole (POZ) vs. fluconazole in the prophylaxis against development of invasive fungal infections (IFI).


Condition Intervention Phase
Mycoses
Drug: Posaconazole oral suspension
Phase III

MedlinePlus related topics:   Fungal Infections   

Drug Information available for:   Posaconazole   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Prevention, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Further study details as provided by Schering-Plough:

Estimated Enrollment:   600
Study Start Date:   February 1998
Estimated Study Completion Date:   December 2003

Detailed Description:

This study is designed to determine the safety, tolerance and efficacy of POZ used as prophylaxis of IFI in high-risk subjects with Grade II-IV acute graft vs. host disease (GVHD) or extensive chronic GVHD. The primary objective is to assess the efficacy of SCH56592 vs fluconazole in preventing proven or probable IFI within the time period from randomization to 16 weeks after the start of treatment with study drug.

  Eligibility
Ages Eligible for Study:   13 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • Hematopoietic progenitor cell transplant subjects with chronic or Grade II-IV acute GVHD being treated with high dose immunosuppressive therapy.
  • One of the following to the subject's prior immunosuppressive regimen:

    1. at least 1mg per kg per day of methylprednisolone or equivalent,
    2. Antithymocyte globulin (ATG) for the therapy of acute GVHD,
    3. Tacrolimus, mycophenolate mofetil, or other steroid-sparing immunosuppressive regimen.
  Contacts and Locations

No Contacts or Locations Provided
  More Information


Publications indexed to this study:

Study ID Numbers:   C/I98-316
First Received:   May 1, 2002
Last Updated:   May 31, 2006
ClinicalTrials.gov Identifier:   NCT00034645
Health Authority:   United States: Food and Drug Administration

Keywords provided by Schering-Plough:
Allogenic Stem cell transplantation  
Fungal infections  

Study placed in the following topic categories:
Mycoses
Clotrimazole
Graft versus host disease
Miconazole
Tioconazole
Graft vs Host Disease
Posaconazole
Homologous wasting disease

Additional relevant MeSH terms:
Trypanocidal Agents
Anti-Infective Agents
Antiparasitic Agents
Antiprotozoal Agents
Therapeutic Uses
Antifungal Agents
Antibiotics, Antifungal
Pharmacologic Actions

ClinicalTrials.gov processed this record on November 30, 2008




Links to all studies - primarily for crawlers